Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacytidine Combined With Chidamide in Relapsed/Refractory Angioimmunoblastic T-cell Lymphoma
NCT05179213Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine and tucidinostat in angioimmunoblastic T-cell lymphoma (AITL), sponsored by Peking Union Medical College Hospital. Primary endpoint: Overall Response Rate at 1 year. Status: unknown.
02
Drugs
azacitidinetucidinostat
03
Conditions
angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on NCT05179213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05179213.